Karyopharm Therapeutics (KPTI) Stock Forecast & Price Target

Karyopharm Therapeutics is supported by a compelling pipeline-led thesis centered on selinexor, whose XPO1 inhibition restores nuclear retention of p53 and other tumor suppressors, creating a biologically differentiated mechanism in hard-to-treat cancers. The strongest catalyst is XPORT-EC-042 in TP53 wild-type advanced/recurrent endometrial cancer, where SIENDO subgroup data showed a 65% reduction in progression or death and mPFS of 39.5 months versus 4.9 months, while the company also sees endometrial cancer as a meaningful revenue expansion opportunity. Financially, XPOVIO generated $114.9 million of U.S. net revenues in 2025, cash extends into 3Q:26, and the Phase III SENTRY myelofibrosis data added credibility with 49.8% SVR35 and a 57% reduction in death risk, despite the Abs-TSS miss.

Karyopharm Therapeutics is facing a fundamentally fragile outlook because its value depends heavily on selinexor approvals and commercial execution across a limited set of indications, including relapsed/refractory multiple myeloma, myelofibrosis, and endometrial cancer. The company’s own assumptions assign only 35% and 70% probabilities of approval in myelofibrosis and endometrial cancer, while the Phase III SENTRY trial missed the Abs-TSS co-primary endpoint, increasing regulatory risk and calling into question the breadth of XPOVIO’s growth prospects. With a projected market value of $457M, outstanding debt, likely need for additional capital, and long-term dilution risk, the balance of clinical, regulatory, and financing pressures supports a negative stance.